Category: Medical
New Hope: STELARA Seeks FDA Approval for Kids with UC
Johnson & Johnson has submitted an FDA request for STELARA approval in pediatric ulcerative colitis patients. This could become the first biologic targeting dual inflammation pathways specifically for children with UC, offering new hope for families with limited treatment options.
Penn State Breakthrough Could Transform IBD Treatment Forever
Penn State researchers are studying gut bacteria interactions to develop treatments that could address IBD at its root cause rather than just managing symptoms. This groundbreaking microbiome research could lead to personalized probiotics and targeted therapies.
After Surgery, IBD Can Still Surprise Us: A Facial Wound’s Message
A woman who thought her ulcerative colitis was cured by surgery developed a rare facial skin condition years later, revealing that IBD can continue affecting the body in unexpected ways. This case highlights why ongoing vigilance and comprehensive care remain important even after major IBD surgery.
New Once-Monthly UC Treatment Approved: What Patients Need to Know
The FDA has approved Omvoh, the first once-monthly injection for ulcerative colitis maintenance therapy. This breakthrough could significantly reduce treatment burden for people with moderate to severe UC.
25-Year Mystery Solved: Why Your Gut Can’t Heal from Crohn’s
After 25 years of research, scientists have finally identified why Crohn’s disease prevents gut healing—immune cells get stuck in attack mode and can’t hear the signals telling them to start repairing tissue. This breakthrough could lead to targeted therapies that restore your body’s natural healing abilities.
AI Revolution: New Hope for Better IBD Management and Care
Artificial intelligence is revolutionizing IBD care with the potential to predict flares, personalize treatments from the start, and give patients more control over their condition. While still developing, these AI advances represent genuine hope for better management of Crohn’s disease and ulcerative colitis.
The Game-Changing Care Model That’s Reducing IBD ER Visits by 22%
New research shows nurse practitioner-led IBD clinics are reducing emergency room visits by 22% and hospitalizations by 52%. This game-changing care model offers hope for more proactive, accessible IBD management that keeps patients stable and out of crisis.
New Crohn’s Drug Shows Promise in Major Clinical Trial
Chugai Pharmaceutical announces promising Phase III results for crovalimab, a new Crohn’s disease treatment showing significant improvements in both symptom relief and intestinal healing. We analyze what this breakthrough could mean for the IBD community.
The Long Road to Diagnosis: Why Getting Crohn’s Answers Takes So Long
Many Crohn’s patients see multiple doctors before getting diagnosed, facing dismissal and misdiagnosis along the way. Understanding why this happens and how to advocate for yourself can help you navigate the healthcare system more effectively and find the answers you deserve.
Breakthrough Stem Cell Therapy Shows Promise for Perianal Fistulas
The STOMP2 clinical trial shows promising results for AU-101, a stem cell therapy using patients’ own cells to heal Crohn’s perianal fistulas. This breakthrough represents a fundamental shift from managing symptoms to promoting lasting tissue repair and healing.
